EUREMAB

EUREMAB is an Italian biotech company and a spinoff of the University of Torino. It fosters and supports the launching of biotech startups with disruptive innovation potential. Much more than a service provider, it gives life to game-changing ideas in the field of biotechnology, drug discovery and healthcare. Did you know that EUREMAB originates from a collaboration between the University of Torino and the Belgian biotech argenx? Did you know that EUREMAB co-founded and launched another successful Belgian biotech, AgomAb Therapeutics? Did you know that EUREMAB has developed the first agonistic antibodies for the treatment of fibrosis? To find out what's cookin' at EUREMAB, follow this page and stay tuned!